Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAF versus TDF in liver transplant recipients with chronic hepatitis B and chronic kidney disease
ACTRN12616000898459Phase 2Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tenofovir alafenamide and tenofovir disoproxil fumarate in Chronic Hepatitis B (CHB) (3 arms), sponsored by Gilead Sciences. Primary endpoints: Change from baseline in renal function at Week 24 and HBV DNA suppression at Week 24. Started Sep 2016; status: active, not recruiting.
02
Drugs
tenofovir alafenamidetenofovir disoproxil fumarate
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ACTRN12616000898459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616000898459.